Aktis Oncology (AKTS) Form 3 stake disclosed by Vida Ventures LLC

Rhea-AI Filing Summary

Vida Ventures II, LLC and Vida Ventures II-A, LLC filed an initial Form 3 as 10% owners of Aktis Oncology, Inc. (AKTS), reporting indirect holdings of the company’s preferred stock. The filing shows Series A and Series B Redeemable Convertible Preferred Stock that each convert into common stock on a 3.8044-for-1 basis with no expiration date. All shares of both preferred series will automatically convert into common stock immediately prior to the closing of Aktis Oncology’s initial public offering, without any additional payment. The shares are held through Vida Ventures II and Vida Ventures II-A, with management entities and committee members disclaiming beneficial ownership beyond their pecuniary interest.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Vida Ventures II, LLC

(Last) (First) (Middle)

C/O VIDA VENTURES ADVISORS, LLC

10100 SANTA MONICA BOULEVARD, SUITE 1500

(Street)

LOS ANGELES CA 90067

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/08/2026

3. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Redeemable Convertible Preferred Stock	(1)	(1)	Common Stock	3,900,284	(1)	I	See Footnote(2)
Series A Redeemable Convertible Preferred Stock	(1)	(1)	Common Stock	108,229	(1)	I	See Footnote(3)
Series B Redeemable Convertible Preferred Stock	(4)	(4)	Common Stock	959,086	(4)	I	See Footnote(2)
Series B Redeemable Convertible Preferred Stock	(4)	(4)	Common Stock	26,613	(4)	I	See Footnote(3)

1. Name and Address of Reporting Person^*

Vida Ventures II, LLC

(Last) (First) (Middle)

C/O VIDA VENTURES ADVISORS, LLC

10100 SANTA MONICA BOULEVARD, SUITE 1500

(Street)

LOS ANGELES CA 90067

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

VIDA VENTURES II-A, LLC

(Last) (First) (Middle)

10100 SANTA MONICA BOULEVARD.,

SUITE 1500

(Street)

LOS ANGELES CA 90067

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Each share of Series A Redeemable Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 3.8044-for-1 basis and has no expiration date. All shares of Series A Redeemable Convertible Preferred Stock will automatically convert on a 3.8044-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration.

2. These shares are held by Vida Ventures II, LLC ("VV II"). VV Manager II, LLC ("VVM II") is the manager of VV II and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and Helen Kim, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.

3. These shares are held by Vida Ventures II-A, LLC ("VV II-A"). VVM II is the manager of VV II-A and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II-A. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and Helen Kim, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II-A and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.

4. Each share of Series B Redeemable Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 3.8044-for-1 basis and has no expiration date. All shares of Series B Redeemable Convertible Preferred Stock will automatically convert on a 3.8044-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration.

	VIDA VENTURES II, LLC, By: VV Manager II, LLC, its Manager, By: /s/ Jean-Philippe Kouakou-Zebouah, Authorized Signatory	01/08/2026
	VIDA VENTURES II-A, LLC, By: VV Manager II, LLC, its Manager, By: /s/ Jean-Philippe Kouakou-Zebouah, Authorized Signatory	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Aktis Oncology (AKTS) Form 3 filed by Vida Ventures report?

It reports that Vida Ventures II, LLC and Vida Ventures II-A, LLC are 10% owners of Aktis Oncology, Inc. through holdings of Series A and Series B Redeemable Convertible Preferred Stock.

How are the Series A and Series B preferred shares in AKTS convertible into common stock?

Each share of Series A and Series B Redeemable Convertible Preferred Stock is convertible into Aktis Oncology common stock on a 3.8044-for-1 basis and has no expiration date.

When will the preferred shares reported by Vida Ventures convert into AKTS common stock?

All reported shares of Series A and Series B preferred stock will automatically convert into common stock on a 3.8044-for-1 basis immediately prior to the closing of Aktis Oncology’s initial public offering, without additional consideration.

Are the Aktis Oncology preferred shares held directly by Vida Ventures or through entities?

The filing states that the shares are held by Vida Ventures II, LLC and Vida Ventures II-A, LLC, with VV Manager II, LLC as manager, which may be deemed to have voting, investment and dispositive power over those shares.

Do individuals associated with Vida Ventures fully own the AKTS shares reported on Form 3?

The footnotes explain that committee members, including Arie Belldegrun, Fred Cohen, Leonard Potter, Rajul Jain, Joshua Kazam and Helen Kim, may be deemed to share power over the shares but each disclaims beneficial ownership except to the extent of their pecuniary interest.

Does this AKTS Form 3 show a new purchase or sale by Vida Ventures?

No. As a Form 3, it serves as an initial statement of beneficial ownership and, in the provided data, the transactions are coded as holdings rather than new purchases or sales.